• Ophthotech Corp., of New York, initiated enrollment in a pivotal Phase III trial of lead compound Fovista, an anti-platelet-derived growth factor, which is being studied in combination with anti-VEGF therapy to treat newly diagnosed neovascular age-related macular degeneration (wet AMD).